Trial Profile
A Phase 2, Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of AZD8931 In Combination With Anastrozole, Compared to Anastrozole Alone, in Post Menopausal Women With Hormone Receptor Positive, Endocrine Therapy Naive, Locally Advanced or Metastatic Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Sapitinib (Primary) ; Anastrozole
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms MINT
- Sponsors AstraZeneca; AstraZeneca KK
- 04 Jun 2013 Interim results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 16 Nov 2012 Primary endpoint 'Progression-free-survival-duration' has not been met.
- 16 Nov 2012 Planned end date changed from 1 Aug 2015 to 1 Mar 2013 as reported by ClinicalTrials.gov.